Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:clinicalTrialPhase |
pancreatic cancer
vaccine bladder cancer |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
cell therapies
immunomodulators cancer vaccines |
| gptkbp:focusesOn |
infectious diseases
oncology immunotherapy |
| gptkbp:foundedYear |
2014
|
| gptkbp:founder |
gptkb:Patrick_Soon-Shiong
|
| gptkbp:headquartersLocation |
gptkb:Culver_City,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ImmunityBio, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:mergedInto |
gptkb:NantKwest
|
| gptkbp:notableProduct |
gptkb:Anktiva_(N-803)
|
| gptkbp:numberOfEmployees |
over 300
|
| gptkbp:parentCompany |
gptkb:NantWorks
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:IBRX
|
| gptkbp:tradedOn |
gptkb:NASDAQ:_IBRX
|
| gptkbp:website |
https://www.immunitybio.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:NK
gptkb:NantCell |
| gptkbp:bfsLayer |
7
|